Next generation hemophilia therapies are aimed at revolutionizing the clinical outcomes and quality of life of hemophilia patients. Next generation therapies include bispecific antibodies, next generation recombinant products, and gene therapy. Bispecific antibodies mimic factor VIII or other molecules which function by inhibiting the natural anticoagulants such as antithrombin (AT) and tissue factor pathway inhibitor (TFPI), resulting in downstream hemostasis at the site of bleeding in patients with hemophilia. Next generation recombinant products are intended to extend the half-life of FVIII, resulting in longer infusion intervals. Gene therapy involves introducing genetic material into a patient’s body to deliver a correct copy of a gene to the cells to compensate for a defective one. The therapy is potentially transformational technology aimed at providing highly specialized, one-time treatment that addresses the root cause of the disease caused by genetic mutation.
Increase in initiatives for hemophilia awareness is a key factor driving the global next generation hemophilia therapies market. Hemophilia drug manufacturers and government and non-government organizations are focusing on nationwide campaigns to create awareness about the condition among the general population. Every year the World Federation of Hemophilia (WFH) conducts WFH Annual Global Survey, which aims to collect basic demographic information and data on access to care and treatment products in order to provide hemophilia treatment centers, health officials, and hemophilia organizations with useful and vital information to support efforts to improve or sustain the care to people with bleeding disorders. The aim of these programs and initiatives is to help people affected with hemophilia to seek proper support from health care professionals in addition to imparting awareness about the condition to the population at large in order to break down barriers and address stereotypes present in the society.
The current replacement therapy options used in the management of hemophilia have drawbacks such as frequent dosing with drugs requiring two to three times weekly infusions. This leads to patients developing neutralizing antibodies and also significantly adds to the cost of the treatment. In order to overcome these limitations, hemophilia drug manufacturers are entering into collaboration agreements with other players to develop novel treatment products such as bispecific antibodies, next generation recombinant factors, and gene therapies. In July 2018, Pfizer, Inc. launched phase III program with Spark Therapeutics to evaluate the effectiveness and safety of its FIX replacement gene therapy used in the treatment of hemophilia B.
The global next generation hemophilia therapies market can be segmented based on product type, disease indication, distribution channel, and region. In terms of product type, the next generation hemophilia therapies market can be divided into bispecific antibodies, next generation recombinant factors, and gene therapies. Based on disease indication, the global next generation hemophilia therapies market can be classified into hemophilia A, hemophilia B, and others. In terms of distribution channel, the next generation hemophilia therapies market can be divided into retail pharmacies, hospital pharmacies, and others.
In terms of region, the global next generation hemophilia therapies market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global next generation hemophilia therapies market in 2017 due to collaboration agreements by biopharmaceutical companies aimed at offering enhanced treatment options to manage hemophilia in patients. In May 2017, Pfizer, Inc. and Sangamo Therapeutics, Inc. entered into a global license and collaboration agreement to develop and commercialize gene therapy programs for hemophilia A which includes SB-525, the latter’s four lead product candidates. The aim of the collaboration agreement was to offer patients with highly specialized, one-time treatment options with gene therapy in order to address the root cause of the condition. Europe and Asia Pacific were the other major markets for next generation hemophilia therapies.
Prominent players operating in the global next generation hemophilia therapies market include Pfizer, Inc., Shire plc, Sanofi, F. Hoffmann-La Roche Ltd., and Novo Nordisk A/S.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.
TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.
Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:
Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.
Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.
Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.